Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2016

View Archived Issues

Antares Pharma reports safety results from phase III trial of Quickshot testosterone

Vical starts phase II trial of VCL-HB01 in HSV-2 infection

FDA grants fast track designation to Axovant's intepirdine

Biogen completes rolling submission of NDA for nusinersen to FDA

Summit Therapeutics gains FDA fast track status for ezutromid

Versartis starts phase III trial of somavaratan in children with GHD

Abbvie submits sNDA to the FDA for ibrutinib

Cerecor acquires exclusive rights from Eli Lilly for CERC-611

FDA issues complete response letter for Remoxy extended-release capsules

HSP90 inhibitor/SN-38 drug conjugate STA-8666 effective in pediatric sarcoma models

Phase III COLUMBUS trial of encorafenib plus binimetinib meets primary endpoint

Novartis patents angiotensin AT2 receptor antagonists

Emory University discloses RNA-directed RNA polymerase inhibitors

Merck & Co. describes IRAK-4 inhibitors

BioMarin Pharmaceutical develops CGS inhibitors

LTT Bio-Pharma presents muscarinic M3 receptor antagonists

FDA grants emergency use authorization for Vela Diagnostics' Zika virus molecular assay

Alpha4betadelta GABARs exert anticonvulsant effects during puberty

Circulating C19MC microRNAs as biomarkers of infantile hemangioma

Idera Pharmaceuticals reports initial data from phase I/II trial of IMO-2125

Novel GLP-1/FGF21 dual agonist in preclinical studies

Pfizer not to split into two separate companies

Sciclone Pharmaceuticals reports advancements in several trials for thymalfasin and PT-112

New start-up Ilkos Therapeutics gets launched for the development of S-42909

Novel hybrid peptides as a promising strategy for type 2 diabetes

FDA places phase III Multikine trial on clinical hold

ARNT2 shows promise as a therapeutic target in MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Probing bidirectional cancer-autoimmune link can yield new targets
BioWorld Science
Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.